"We are keen to begin developing guidance that will help to inform their decisions about treatment and healthcare in these areas as soon as possible and we will publish details of the timetables for these topics on our web site shortly.
NICE has also been asked to appraise adalimumab for moderate to severely active Crohn%u2019s disease.
The National Institute for Health and Clinical Excellence (NICE) today welcomes the announcement of additional topics for its forward work programme. Topics including new treatments for breast and lung cancer, Crohns disease, ulcerative colitis, obesity and rheumatoid arthritis, have been referred to NICE by the Secretary of State for Health in line with the national priorities they have established for the NHS.
The following topics have been referred:
2 clinical guidelines on:
o Rheumatoid arthritis in adults
o Diarrhoea and vomiting in children
1 rapid clinical guideline on:
o Acutely ill patients in hospital
5 technologies for appraisal as part of NICEs rapid single technology appraisal (STA) programme on:
o Bevacizumab for non-small cell lung cancer
o Certolizumab pegol for rheumatoid arthritis
o Infliximab for ulcerative colitis
o Lapatinib for advanced or metastatic breast cancer
o Rimonabant for the treatment of obese and overweight patients
3 technologies for appraisal as part of NICEs multiple technology appraisal (MTA) programme on:
o Endovascular stents for abdominal aortic aneurysms
o Machine versus cold (static) storage of donated kidneys
o Spinal cord stimulation for chronic pain
In addition, NICE has also been asked to appraise adalimumab for moderate to severely active Crohns disease. It has not yet been confirmed whether this will be appraised as part of the Institutes MTA or STA programmes.
Commenting on the referrals, Andrew Dillon, NICE Chief Executive said: NICE welcomes the referral of todays topics, which address areas of significant concern for those working in the NHS, patients and carers. We are keen to begin developing guidance that will help to inform their decisions about treatment and healthcare in these areas as soon as possible and we will publish details of the timetables for these topics on our web site shortly.
Advertise in this space for $10 per month.
Contact us today.
This news story has been reviewed by Dr. Rashmi Yadav before its publication on RxPG News website. Dr. Rashmi Yadav, MBBS, is a senior editor for RxPG News. In her position she is responsible for managing special correspondents and the surgery section of the website. Her areas of special interest include cardiothoracic surgery and interventional radiology.
RxPG News is committed to promotion and implementation of Evidence Based Medical Journalism in all channels of mass media including internet.
Additional information about the news article
3. The National Institute for Health and Clinical Excellence (NICE) is the independent organisation responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health.
4. NICE produces guidance in three areas of health:
public health guidance on the promotion of good health and the prevention of ill health for those working in the NHS, local authorities and the wider public and voluntary sector
health technologies guidance on the use of new and existing medicines, treatments and procedures within the NHS
clinical practice guidance on the appropriate treatment and care of people with specific diseases and conditions within the NHS.
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use